Critics knock JAMA study linking testosterone drugs to cardio risks

Carly Helfand A study the FDA has cited as a reason to investigate the cardiovascular safety of testosterone drugs has come under heavy fire from critics. Physicians and researchers ...

J&J, Medivir get EU nod for their hep C drug Olysio

Eric Palmer The horse race for oral treatments of chronic hepatitis C entered another turn today as the European Union recommended approval of Olysio, the Johnson & Johnson and ...

Chelsea Therapeutics and the return of pharma’s phantom checkbook

Damian Garde Chelsea Therapeutics saw its shares soar roughly 15% on Thursday thanks to rumors that it could be in line for a Big Pharma buyout. But a deeper look at the issue reveals ...

GSK touts Anoro results as it preps for generic attacks on $8B-seller Advair

Carly Helfand With aging top dog Advair losing ground to generic and branded competitors alike, GlaxoSmithKline is grooming a lineup of respiratory up-and-comers to step in with their ...

Idenix takes to Europe with its Gilead patent spat

Damian Garde Idenix Pharmaceuticals believes Gilead Sciences violated its patents with the blockbuster-selling hepatitis C pill Sovaldi, and the biotech has expanded its legal fight ...

FDA rejects Durect’s pitch to market post-operative pain therapy

John Carroll FierceBiotech News

Singapore fling: AbbVie says a plant in Asia is just what it needs

Eric Palmer Humira, the best-selling drug in the world, continues to power the top and bottom lines for the year-old pharma spinoff AbbVie. But the drugmaker has a pipeline of new products ...

Medigene gambles on dendritic cell cancer vaccines in Trianta buyout

John Carroll Germany's Medigene AG has nabbed a small cancer vaccine developer in a buyout which will add a team of investigators from one of the country's top research institutes. ...

NuPathe nixes Endo’s buyout offer to hook up with Teva

Tracy Staton FiercePharma News

J&J shipping out diagnostics biz for $4.2B

Damian Garde After more than a year of less-than-clandestine sale efforts, Johnson & Johnson has found a buyer for its diagnostics unit, signing a $ 4.2 billion deal with Carlyle ...

Roche’s dealmakers at pRED will continue their global shopping spree in 2014

John Carroll Over the past year John Reed has been tasked with engineering a turnaround at Roche's big pRED research organization, executing a string of new deals aimed at beefing ...

Celgene looks to double its sales by 2017 on wave of cancer drug growth

Tracy Staton Celgene figures it will end 2014 with $ 7.4 billion in net sales, adding about $ 1 billion to its $ 6.4 billion total for 2013. But by 2017, the company figures it will ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS